Compare Stocks

Canada House Cannabis Group Inc., through its subsidiaries, provides medical grade cannabis products in Canada. The company offers cannabinoid therapy products and services to patients, as well as owns and operates medicinal cannabis clinics. It also provides a cloud-based software that links physicians, providers, and patients to data that supports treatment with medical cannabis. The company serves its products under the Abba Medix, ICM Air, ICM Fogo, H-Series, Fleurs de chez nous, and Vandoos brand names. Canada House Cannabis Group Inc. is headquartered in Pickering, Canada.

Diadexus, Inc. engages in the research, development, and commercialization of pharmaceutical products. Its portfolio intends to treat cardiovascular diseases. The company was founded on November 27, 1995 and is headquartered in South San Francisco, CA.

PreveCeutical Medical Inc., a health sciences company, engages in the development of options for preventive and curative therapies utilizing organic and nature identical products. Its pipeline products include Cannabinoid Sol-Gel Delivery, a cannabinoid-based nose-to-brain delivery system that provides relief from various indications, including pain, inflammation, seizures, and neurological disorders; BSV Peptide Program for targeting cancer progression; Non-Addictive Analgesic for pain management; and Dual Gene Therapy for type 2 diabetes and obesity. The company also develops a range of medicinal cannabis-based products. PreveCeutical Medical Inc. is headquartered in Vancouver, Canada.

Relief Therapeutics Holding AG, a biopharmaceutical company, focuses on identification, development, and commercialization of novel, patent protected products for the treatment of metabolic, dermatological, and pulmonary rare diseases in Switzerland, Europe, North America, and internationally. The company offers SETOFILM/ONDISSOLVE for radiotherapy induced nausea and vomiting, and chemotherapy induced nausea and vomiting, as well as postoperative induced nausea and vomiting. It develops RLF-100, a synthetic form of vasoactive intestinal peptide (VIP) for the treatment of acute respiratory distress syndrome (ARDS) associated with COVID-19, nonCOVID-19-related ARDS, pulmonary sarcoidosis, checkpoint inhibitor-induced pneumonitis, and chronic berylliosis. The company also develops RLF-TD011, a hypochlorous acid topical sprayable solution to treat wound colonization, reduce local inflammation, alleviate symptoms, and hasten wound healing in epidermolysis bullosa. In addition, it develops OLPRUVA, a sodium phenylbutyrate for the treatment of various inborn errors of metabolism, urea cycle disorders, and maple syrup urine disease; APR-OD32, which is in phase 1 for the treatment of patients with phenylketonuria. Relief Therapeutics Holding AG was founded in 2013 and is based in Geneva, Switzerland.

Tengion, Inc. is a medicine company, focuses on discovering, developing, manufacturing and commercializing of neo-organs and products. The company was founded by Steven Nichtberger and David I. Scheer on July 10, 2003 and is headquartered in Winston-Salem, NC.